Scripps Research Institute has evolved into a new model that moves scientific breakthroughs in its academic labs into preclinical and initial clinical studies that translate those findings into proof-of-concept for new drug candidates. That new model includes a novel way to fund that translational work that turns ideas into valuable assets worthy of biopharmaceutical company investment.
Scripps President and CEO Peter Schultz, after he was named CEO in 2015, eventually merged the nonprofit translational medicine group...